Has Glenn Harnett received payments from drug or device companies?

Yes. Drug and device makers reported $113,074 in general payments to Glenn Harnett across 39 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Glenn Harnett did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Glenn Harnett come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Glenn Harnett

General Practice · Hoover, ALNPI 1982644407

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $103,647 of the $113,074 with a category attached, or 91.7%. 6 manufacturers reported payments, led by Visby Medical, Inc. at 38.9% of the total. Reporting peaked in 2023 at $28,248 and has fallen 87.5% since, to $3,542 in 2025. Among general practice clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$113,074in general payments, 2019–2025

Across 39 payments — averaging $2899.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Visby Medical, Inc.$44K
Biofire Diagnostics, LLC$27K
Melinta Therapeutics, LLC$19K
Abbott$15K
Biomerieux Inc$7K
Roche Molecular Systems, Inc.$2K

$4,425,785in research payments, 2019–2025

Across 161 payments — averaging $27,489 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Visby Medical, Inc.$2M
Cepheid$893K
Orasure Technologies Inc.$592K
Sekisui Diagnostics LLC$414K
Roche Molecular Systems, Inc.$366K
Talis Biomedical Corporation$85K
plus $83K from 2 others

What the payments were for

Consulting fees$103,64792%
Speaking & faculty fees$2,4002%
Travel & lodging$6,8526%
Food & beverage$1750%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Visby Medical, Inc.	6	$44,002
Biofire Diagnostics, LLC	4	$26,975
Melinta Therapeutics, LLC	2	$18,508
Abbott	21	$14,583
Biomerieux Inc	5	$6,606
Roche Molecular Systems, Inc.	1	$2,400

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Film Array$26,950
Visby Medical Sexual Health Click Test$24,873
Visby Medical Respiratory Health Test$19,129
ID NOW INSTRUMENT$6,603

How this compares

$113,074 in reported general payments places this provider in the 95th percentile of 1,114 general practice providers in Alabama.

See all general practice providers in Alabama →

Other general practice in Hoover

James LecroyHoover$3K
Frank TombrelloBirmingham$163K
Bradley WillisMontgomery$151K
Ashley McIntyreMontgomery$123K
John BurgessBirmingham$117K
Alan ColemanAthens$30K
Darrell DoucetteHuntsville$20K
Earl RogersMobile$19K
Jennifer DoobrowCullman$16K
Robert SchusterDadeville$12K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →